Idasanutlin
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Idasanutlin (Roche) is an oral inhibitor of the murine double minute 2 (MDM2) protein, which blocks the interaction of MDM2 with the p53 tumor suppressor. Inhibition of MDM2/p53 interaction by idasanutlin restores the tumor-suppressing function of the p53 protein and has been shown to induce apoptosis of cancer cells in preclinical models.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 idasanutlin : Acute myeloid leukemia (AML)
LIST OF FIGURES
8 Figure 1: Idasanutlin for acute myeloid leukemia – SWOT analysis
9 Figure 2: Datamonitor Healthcare’s drug assessment summary of idasanutlin for acute myeloid leukemia
10 Figure 3: Datamonitor Healthcare’s drug assessment summary of idasanutlin for acute myeloid leukemia
LIST OF TABLES
5 Table 1: Idasanutlin drug profile
6 Table 2: Idasanutlin Phase III trial in acute myeloid leukemia
7 Table 3: Idasanutlin Phase I/Ib data in acute myeloid leukemia
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Victoza 
Sign up to the